Sorrento can still apply for EUA's in Brazil and the US for ABIVERTINIB(COVID). The pivotal phase 3 will then be for longer term approval.
COVIDROPS and COVI-MSC are in phase 2 trials(both safety and efficacy). They too could receive EUA's on the basis of interim analysis if the results are so good that it is unfair to placebo patients to deny them access to these trial drugs!
In any case look to rapid enrollment in Sorrento Covid trials as word spreads about the fine results in the ABIVERTINIB trials!
Market Data 
Markets 
AI
